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Abstract 
Background: Cardiac complications constitute a rare clinical manifestation of cytomegalovirus (CMV) infection. This 
virus is usually asymptomatic in immunocompetent individuals. We report a case of myocarditis and cardiac insuffi-
ciency due to primary CMV infection. Serological tests by using ELISA method showed positive results for the virus.
Case presentation: A 41-year-old man with no prior comorbidities presenting with dyspnoea, fever, and oedema 
was admitted to the cardiac emergency service. He had fever and dry cough, which aggravated into progressive res-
piratory distress, lower limb oedema, and orthopnoea 30 days prior to hospitalisation. The electrocardiogram revealed 
sinus tachycardia, first-degree right bundle branch block, and ventricular and left atrial overload as well as diffuse and 
nonspecific disturbances of ventricular repolarization. Serological tests were conducted, and IgM (1.54 UI/mL) and 
IgG (2.5 UI/mL) were found positive only for CMV by using ELISA. The patient was diagnosed with cardiac insufficiency 
due to CMV myocarditis. He was treated with ganciclovir for 10 days and received supportive medication.
Conclusion: This case reaffirms the possibility of cardiac involvement in CMV infection and emphasises the  
importance of viral aetiologies as differential diagnoses for acute myocarditis.
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Background
Cytomegalovirus (CMV) infection is a prevalent infec-
tious disease worldwide; however, its prevalence varies 
with geographical regions and socioeconomic statuses 
[1]. CMV belongs to the Herpesviridae family and Beta-
herpesvirinae subfamily type 5; it is a DNA virus with the 
ability of remaining latent for a long time [2]. Its preva-
lence ranges from 30 to 100 % in the general population 
with prior exposure to the virus as determined by sero-
logical tests. This prevalence is inversely proportional 
to socioeconomic status and directly proportional to 
age [3]. Adults and adolescents, such as day-care work-
ers and school teachers, are at higher risk for acute CMV 
infection because of the close contact with children 
who may be infected [1]. Primary infection is usually an 
asymptomatic event in immunocompetent individu-
als. However, there are clinical presentations that are 
described as classic influenza-like syndrome or mono-
nucleosis-like syndrome with symptoms of the classic 
fever, pharyngitis, and lymphadenopathy triad [1, 5]. The 
intensity and clinical symptoms vary and include sys-
temic disorders such as hepatitis, hematologic diseases, 
or meningoencephalitis; additionally, it can be associated 
with high mortality rates [2, 4, 5].
Cardiovascular complications constitute a rare mani-
festation of CMV infection; it is a diagnostic challenge 
in the emergency cases [4]. We describe a previously 
healthy man who developed myocarditis and cardiac 
insufficiency due to primary CMV infection.
Open Access
BMC Research Notes
*Correspondence:  palmeiramm@ig.com.br 
4 60 Amazonas square, Jurunas, 66025-070 Belém, PA, Brazil
Full list of author information is available at the end of the article
Page 2 of 5Magno Palmeira et al. BMC Res Notes  (2016) 9:391 
Case presentation
A 41-year-old man, unemployed, brown, parent of two 
school-age children, with no prior comorbidities, and 
presenting with dyspnoea, fever, and oedema was admit-
ted to the cardiac emergency service. The patient had 
undergone no related interventions in the past and had 
no cardiac risks based on his family history.
He had fever and dry cough, which aggravated into 
progressive respiratory distress, lower limb oedema, 
and orthopnoea 30  days prior to hospitalisation. Physi-
cal examination revealed fever (38  °C), pallor (++/4+), 
dyspnoea, tachycardia [heart rate (HR) = 136 bpm], car-
diac gallop rhythm (presence of S3), mitral systolic mur-
mur as well as absent breath sounds at the lung base, 
and crackles and rales up to the middle third of both 
the lungs. Additionally, he experienced hepatomegaly, 
splenomegaly, painless oedema, positive pitting oedema 
(++++/4+) of the lower limbs, bruises, and petechiae 
(Fig. 1).
The electrocardiogram revealed sinus tachycardia, first-
degree right bundle branch block, and ventricular and 
left atrial overload as well as diffuse and nonspecific dis-
turbances of ventricular repolarization (Fig. 2). The chest 
radiographs revealed bilateral pleural effusion in the lung 
base and an enlarged cardiac silhouette (Fig. 3). A tran-
sthoracic echocardiogram revealed 35 % ejection fraction 
(EF) of the left ventricle (LV) and an increase in the left 
cavity (70  mm LV). Coronary angiography revealed no 
obstructive atherosclerosis lesions in the coronary artery.
Serological tests were conducted for HIV-1 and HIV-
2, hepatitis B and C, CMV, and Chagas disease. The 
serological tests results were negative for all the viruses 
except CMV, which included positive results for IgM 
(1.54 UI/mL) and IgG (2.5 UI/mL) by using ELISA.
Laboratory-based tests conducted upon admission 
revealed the following: haemoglobin level, 9.15 g/dL; leu-
kocyte number, 8400/mm3; segmented neutrophil frac-
tion, 77.5  %; platelet number, 289,000/mm3; unchanged 
coagulation; erythrocyte sedimentation rate, 120  mm/h; 
and C-reactive protein (CRP) level, 96 mg/dL. Troponin 
I level increased but the creatinine kinase-MB level did 
not increase (3.12 and 2.1  ng/mL, respectively). The 
renal scores and ionogram values were within the refer-
ence values. In addition, the patient showed significantly 
increased levels of canalicular liver enzymes [alkaline 
phosphatase (ALP) and gamma glutamyl transferase 
(GGT)] during hospitalisation.
The patient was diagnosed with cardiac insufficiency 
due to CMV myocarditis. He was administered 250 mg of 
ganciclovir IV twice a day for 10 days and received sup-
portive medication that included oral administration of 
0.25 mg of digoxin once a day, 50 mg of losartan twice a 
day, 25 mg of carvedilol twice a day, 40 mg of furosem-
ide twice a day, and 25 mg of spironolactone once a day. 
After receiving the anti-viral medication, the patient’s 
liver enzyme levels decreased, as revealed by laboratory-
based tests (Fig. 4); in addition, the hepatosplenomegaly 
improved. Abdominal CT was performed following 
the drug therapy, and normal liver characteristics were 
revealed with no biliary tract dilatation. The ecchymotic 
spots and petechiae that were observed upon admission 
and that had emerged during the course of infection were 
also treated.
The patient showed improvement in clinical and labo-
ratory-based tests and was discharged in functional class 
I (New York Heart Association) after 14  days of hospi-
talisation. The serological tests confirmed CMV infection 
(IgM, 0.9 UI/mL and IgG, 10.1 UI/mL). One month after 
discharge, routine echocardiography revealed a 75  % 
EF of the LV and almost normal values for the diameter 
of the left chambers. The cardiac enzyme levels were 
normal.
Discussion
Generally, in immunocompetent adults, CMV infec-
tion is either asymptomatic or involves a typical disease 
course similar to a self-limited mononucleosis-like syn-
drome. The infection rarely causes severe complications 
of specific organs; however, acute gastrointestinal, cardi-
ovascular, neurological, and/or liver disorders have been 
reported [1].
Evidence of cardiac events, particularly acute pericar-
ditis or myocarditis due to CMV infection, is uncommon 
in immunocompetent patients without any associated risk 
Fig. 1 Patient’s lower limbs presenting with severe oedema, 
ecchymosis, and petechiae. Patient presented with painless oedema, 
positive pitting oedema (++++/4+) of the lower limbs, ecchymosis, 
and petechiae
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factor [4]. Normally, these changes occur asymptomatically 
and, in most cases, are diagnosed as incidental findings 
during the typical course of mononucleosis-like syndrome 
[4, 5]. However, there may occasionally be serious com-
plications associated with infection, such as cardiogenic 
shock, tamponed, or acute cardiac insufficiency [5].
The diagnosis of myocarditis is a constant challenge in 
medical practice because of high clinical variability and 
high risk of sudden death, which can progress to dilated 
cardiomyopathy in approximately 10 % of these patients 
[6]. Myocarditis is defined as inflammation of the heart 
muscle and may involve the myocytes, interstitium, vas-
cular elements, and pericardium [6]. Infectious agents, 
especially viral agents, are the most important etiologic 
agents [7].
Owing to their risks and high costs, use of endo-
myocardial biopsies for making diagnoses remains 
controversial. The incremental diagnostic, prognostic, 
and therapeutic values of risks associated with such an 
invasive procedure must be evaluated. Particularly, such 
an evaluation must be conducted when the aetiology of 
myocarditis, based on positive results of CMV serological 
tests, is very strongly suspected. An excellent clinical out-
come after ganciclovir therapy that included >100 % EF 
increase confirmed the initial diagnosis made by using a 
non-invasive test [8].
Enteroviruses are widely associated with myocarditis 
and dilated cardiomyopathy, and CMV has sporadically 
been implicated in this process. In a survey of etiologic 
agents in cases of ventricular dysfunction designated 
as “idiopathic,” expression of the CMV genome was 
detected in only 0.8 % of the cases [7].
In a study based on myocardial autopsy, the CMV DNA 
was found in 38  % of the patients with myocarditis as 
Fig. 2 Electrocardiogram revealing sinus tachycardia, first-degree right bundle branch block, and other cardiovascular disorders. The electrocar-
diogram reveals sinus tachycardia, first-degree right bundle branch block, and ventricular and left atrial overload, as well as diffuse and nonspecific 
disturbances of ventricular repolarization
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the death cause; in contrast, no CMV DNA was found in 
the control subjects. The authors suggested that an anti-
viral therapy could be potentially effective for treating 
CMV infection in patients with severe acute myocardi-
tis; our study findings are similar to that of this study. We 
observed an excellent clinical outcome after ganciclovir 
therapy [9].
The pathophysiology of viral myocarditis involves 
a complex process characterized by three distinct 
phases: infection of myocytes, production of toxins, 
and immune-mediated cytotoxicity. Thus, injury occurs 
because of the direct cytotoxic effect of the causative 
agent, the secondary immune response caused by the 
infectious agent, cytokine expression in the myocardium, 
and the aberrant induction of apoptosis. It is believed 
that the progression to dilation and contractile dysfunc-
tion occurs in a linear manner and that the manifestation 
of symptoms may occur at any of the three phases [6].
The prognosis appears to be favourable in patients 
who survive the initial critical phase. Certain studies 
have shown a 50–80  % chance of resolving dilated car-
diomyopathy within the first 2 years of the clinical onset 
[6]. In the present case, satisfactory progress was seen 
that included the recovery of ventricular function and 
decreased dilation of the cardiac chambers.
Abnormalities based on liver function tests are often 
reported in immunocompetent adults with clinically 
significant primary CMV infection. The blood levels of 
transaminases frequently increase slightly or moderately; 
however, the levels rarely exceed five times the reference 
values; in addition, the alanine transaminase (ALT) levels 
are more affected than the aspartate transaminase (AST) 
levels are. Increase in ALP, GGT, and total bilirubin levels 
are uncommon [1].
In this case, minimal change was detected in the 
AST and ALT levels, whereas the GGT and ALP levels 
increased significantly, which was expected during viral 
infection. These findings led to a hypothesis of asymp-
tomatic viral cholangitis with a self-limited course due 
to anti-viral therapy. These enzymes decreased during 
therapy, and the abdominal ultrasound examination per-
formed during the patient follow-up revealed no signs of 
gallstones or liver changes.
Additionally, petechiae and ecchymotic spots were 
observed on the lower limbs, which had appeared dur-
ing the course of infection and disappeared a few days 
after the completion of the drug therapy. This trend sug-
gested the possible evolution of infectious purpura ful-
minans caused by CMV infection. Vascular involvement 
by CMV has been reported; this virus induces vascular 
changes and triggers a cascade of events that can gener-
ate perivascular inflammation and even thrombosis [10].
The role of anti-viral therapy in the management of vis-
ceral diseases caused by CMV in immunocompromised 
patients, particularly transplant recipients, has been well 
established. However, the use of these agents in immu-
nocompetent individuals is not well established, and no 
definitive conclusion has been established regarding their 
indication [4]. Nevertheless, several studies indicate the 
benefits of using anti-viral therapy, particularly during 
the acute phase of viral infection and in severe cases [6].
In the present case, the acute nature of the viral infec-
tion and the severity of the clinical situation prompted us 
specifically to provide ganciclovir therapy. The outcome 
Fig. 3 Chest radiograph showing cardiomegaly and bilateral pleural 
effusions in the lung bases. The chest radiographs reveal bilateral 
pleural effusion in the lung base and an enlarged cardiac silhouette
Fig. 4 Laboratory tests-based evolution of liver enzymes during gan-
ciclovir therapy. After receiving the anti-viral medication, the patient 
exhibited a regression in his liver enzyme levels based on laboratory 
tests; changes are shown from day 1 to day 6 of the therapy
Page 5 of 5Magno Palmeira et al. BMC Res Notes  (2016) 9:391 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
was favourable and included the resolution of symptoms 
and a marked improvement of the cardiac, respiratory, 
and liver manifestations after specific anti-viral therapy.
Conclusions
This case reaffirms the possibility of cardiac involvement 
in CMV infection and emphasises the importance of viral 
aetiologies as differential diagnoses for acute myocarditis.
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